Compare ARTW & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTW | FEMY |
|---|---|---|
| Founded | 1956 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.0M |
| IPO Year | 1996 | 2021 |
| Metric | ARTW | FEMY |
|---|---|---|
| Price | $2.38 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 12.9K | ★ 43.2K |
| Earning Date | 04-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | 44.71 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $22,975,408.00 | $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | $54.75 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $2.05 | $0.29 |
| 52 Week High | $4.69 | $6.29 |
| Indicator | ARTW | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 43.88 |
| Support Level | $2.07 | $2.90 |
| Resistance Level | $2.52 | $4.78 |
| Average True Range (ATR) | 0.10 | 0.44 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 43.63 | 4.91 |
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.